Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Befiradol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 18/20 | 0.90 |
| ▸ | DRD2 | P14416 | 1/20 | 0.90 |
| ▸ | DRD4 | P21917 | 1/20 | 0.90 |
| ▸ | DRD3 | P35462 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Befiradol SCHEMBL503073 | 1.00 | HTR1A (0.90) | HTR1ADRD2DRD4DRD3 | |
| Befiradol SCHEMBL29780526 | 1.00 | HTR1A (0.90) | HTR1ADRD2DRD4DRD3 | |
| Befiradol SCHEMBL4546512 | 0.95 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| Befiradol SCHEMBL29408712 | 0.95 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| Befiradol SCHEMBL31214695 | 0.95 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| Befiradol SCHEMBL31214696 | 0.95 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| Befiradol SCHEMBL678174 | 0.95 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| Befiradol SCHEMBL19971703 | 0.89 | HTR1A (0.88) | HTR1ADRD2DRD4DRD3 | |
| SCHEMBL1380782 | 0.88 | HTR1A (0.86) | HTR1ADRD2DRD4DRD3 | |
| SCHEMBL5185385 | 0.88 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088792-A1 | Pyridin-2-YL Methylamine Derivatives for Treating Opiate Dependence | PIERRE FABRE MEDICAMENT (FR) | 2012-04-12 | — | — | US | disclosed |
| US-8106074-B2 | Pyridin-2-yl-methylamine derivatives for treating opiate dependence | PIERRE FABRE MEDICAMENT (FR) | 2012-01-31 | — | — | US | disclosed |
| EP-1406627-B1 | PYRIDIN-2-YL-METHLYAMINE DERIVATIVES FOR TREATING OPIOID DEPENDENCE | PF MEDICAMENT (FR) | 2006-11-08 | — | — | EP | disclosed |
| US-20050065348-A1 | Pyridin-2-yl-methylamine derivatives for treating opioid dependence | PIERRE FABRE MEDICAMENT (FR) | 2005-03-24 | — | — | US | disclosed |
| EP-1406627-A1 | PYRIDIN-2-YL-METHLYAMINE DERIVATIVES FOR TREATING OPIOID DEPENDENCE | PIERRE FABRE MEDICAMENT (FR) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003006020-A1 | PYRIDIN-2-YL-METHLYAMINE DERIVATIVES FOR TREATING OPIOID DEPENDENCE | PIERRE FABRE MEDICAMENT (FR) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088792-A1 | Pyridin-2-YL Methylamine Derivatives for Treating Opiate Dependence | OPRK1, OPRM1, OPRD1 | HTR1A 63/4885DRD2 74/4885DRD4 243/4885 |
| US-20050065348-A1 | Pyridin-2-yl-methylamine derivatives for treating opioid dependence | OPRM1, OPRK1, OPRD1 | HTR1A 59/4885DRD2 44/4885DRD4 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.